Appointment of Company Secretary
Released
Released
Announcement PDF
Appointment of Company Secretary
24 May 2024: PharmAust Limited (ASX: PAA & PAAOA) (“PharmAust” or “the Company”) is pleased to
announce the appointment of Mr Stefan Ross as Company Secretary, effecfive 24 May 2024.
Mr Ross has over 10 years’ experience in accounfing and secretarial services for ASX listed companies.
His extensive experience includes ASX compliance, corporate governance control and implementafion,
statutory financial reporfing and board and secretarial support.
Mr Ross will be the person responsible for communicafions with the ASX in relafion to Lisfing Rule
mafters under Lisfing Rule 12.6.
This announcement is authorised for release by the Board of Directors of PharmAust Limited.
For further informafion, please contact:
John Clark
Managing Director
investorenquiries@pharmaust.com
P: +61 (8) 9202 6814
F: +61 (8) 9467 6111
W: www.pharmaust.com
Media:
Mafthew Wright
NWR Communicafions
maft@nwrcommunicafions.com.au
0451 896 420
About PharmAust Limited:
PharmAust Limited is listed on the Australian Securifies Exchange (ASX Code: PAA). PAA is a clinicalstage biotechnology company developing therapeufics for human and animal health applicafions. The
company is focused on repurposing monepantel (MPL) for human neurodegenerafive diseases.
MPL is a potent and safe inhibitor of the mTOR pathway. This pathway plays a central role in the growth
and proliferafion of cancer cells and degenerafing neurons. The mTOR pathway regulates the cellular
“cleaning process,” where toxic protein is broken down into macromolecules to be reused. This
autophagic process is disrupted in most neurodegenerafive diseases, including motor neuron disease
(MND/ALS).
PAA’s lead MPL program is for the treatment of MND/ALS, a rare, incurable disease. The company
recently announced posifive top-line results for its Phase 1 study in pafients with MND/ALS. PAA
PharmAust Limited ABN 35 094 006 023. Suite 116, 1 Kyle Way, Claremont, Western Australia
Tel: 08 9202 6814 Fax: 08 9467 6111
www.pharmaust.com
anficipates commencing enrolment in its pivotal registrafion adapfive Phase 2/3 clinical study in H2 CY
2024 that could lead to accelerated approval with the US Food and Drug Administrafion in 2026.
The Neurodegenerafive Disease Market size is esfimated at USD 55.12 billion in 2024, and is expected
to reach USD 77.82 billion by 2029, growing at a CAGR of 7.14% during the forecast period (20242029).1
1 hftps://www.mordorintelligence.com/industry-reports/neurodegenerafive-disease-market
PharmAust Investor Hub:
We encourage you to ufilise our Investor Hub for any enquiries
regarding this announcement or other aspects concerning PharmAust.
This plafform offers an opportunity to submit quesfions, share
comments, and view video summaries of key announcements.
Access the investor hub by scanning the QR code or visifing:
hftps://investorhub.pharmaust.com/
PharmAust Limited ABN 35 094 006 023. Suite 116, 1 Kyle Way, Claremont, Western Australia
Tel: 08 9202 6814 Fax: 08 9467 6111
www.pharmaust.com
Share your feedback
Discover